Drug discovery firm Evotec, owner of the API manufacturer Aptuit, is a member of the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration, which was launched formally on 27 February. This will aim to transform global action on TB, which causes more deaths than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018.
Big Pharma giant Sanofi has announced plans to create a stand-alone company dedicated to the production and marketing of APIs to third parties.
Lonza has announced results for 2019, in which its growth was entirely driven by the Pharma Biotech & Nutrition division on which it will base its future.
CDMO Piramal Pharma Solutions business is to expand its Aurora facility in Aurora, Toronto, by investing C$25 million in a new API wing.
Porton Pharma Solutions, a Chinese custom API services firm, has officially put into use its fermentation pilot laboratory at Chongqing, Sichuan province.
Alcami has agreed to sell its pre-clinical and early stage API facility in Weert, Netherlands, to MercachemSyncom. Terms were not disclosed.
Private equity investor Advent International has acquired Industria Chimica Emiliana (ICE) after 40 years of ownership by the Bortoli family, who developed the first laboratory bile acids.